Format

Send to

Choose Destination
Eur Heart J. 2016 Nov 14;37(43):3260-3266. Epub 2016 Apr 20.

Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?

Author information

1
King's British Heart Foundation Centre, King's College London, London, UK.
2
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
3
Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
4
Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT, USA.
5
King's British Heart Foundation Centre, King's College London, London, UK manuel.mayr@kcl.ac.uk.

Abstract

Recent discoveries have revealed that microRNAs (miRNAs) play a key role in the regulation of gene expression. In this review, we summarize the rapidly evolving knowledge about liver miRNAs (including miR-33, -33*, miR-223, -30c, -144, -148a, -24, -29, and -122) and their link to hepatic lipid metabolism, atherosclerosis and cardiovascular disease, non-alcoholic fatty liver disease, metabolic syndrome, and type-2 diabetes. With regards to its biomarker potential, the main focus is on miR-122 as the most abundant liver miRNA with exquisite tissue specificity. MiR-122 has been proposed to play a central role in the maintenance of lipid and glucose homeostasis and is consistently detectable in serum and plasma. This miRNA may therefore constitute a novel biomarker for cardiovascular and metabolic diseases.

KEYWORDS:

Biomarkers; Cardiovascular disease; Lipid metabolism; MicroRNAs

PMID:
27099265
PMCID:
PMC5146692
DOI:
10.1093/eurheartj/ehw146
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center